Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified.
Saved in:
| Title: | Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified. |
|---|---|
| Authors: | Esler, Murray1 (AUTHOR), Kjeldsen, Sverre E.2 (AUTHOR), Pathak, Atul3 (AUTHOR), Grassi, Guido4 (AUTHOR), Kreutz, Reinhold5 (AUTHOR), Mancia, Giuseppe4 (AUTHOR) |
| Source: | Blood Pressure. Dec2022, Vol. 31 Issue 1, p210-224. 15p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 08037051 |
|---|---|
| DOI: | 10.1080/08037051.2022.2110858 |
